ArticleCurrent treatment options in allergy2017
Atopic Dermatitis: Early Treatment in Children.
Article in Current treatment options in allergy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- Impact of Atopic Dermatitis on the Quality of Life of Children in Ethiopia: A Multicenter Prospective Cohort Study.Children (Basel, Switzerland) · 2026Article
- Article
- A Prospective Observational Study to Evaluate the Actual Use of 1% Pimecrolimus in Chinese Patients with Mild-to-Moderate Atopic Dermatitis Affecting Sensitive Skin Areas.Pragmatic and observational research · 2025Article
- Atopic Dermatitis: A Review of Diagnosis and Treatment.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2024Article
- Topical steroids or emollients: does order matter?Archives of dermatological research · 2024Review
- Dupilumab Treatment in Pediatric Patients Aged 6-11 Years with Severe Atopic Dermatitis Whose Disease Is Not Adequately Controlled: A Review.Drug design, development and therapy · 2024Review
- Pimecrolimus for the Treatment of Atopic Dermatitis in Infants: An Asian Perspective.Dermatology and therapy · 2023Review
- Shedding light on key pharmacological knowledge and strategies for pediatric atopic dermatitis.Expert review of clinical pharmacology · 2023Review
- Ocular manifestations of children with atopic dermatitis in Saudi Arabia.International journal of ophthalmology · 2023Article
- Recent Developments and Advances in Atopic Dermatitis: A Focus on Epidemiology, Pathophysiology, and Treatment in the Pediatric Setting.Paediatric drugs · 2022Review
- Curcumin Ameliorates Ovalbumin-Induced Atopic Dermatitis and Blocks the Progression of Atopic March in Mice.Inflammation · 2020Article
- Patient-Reported Impact of Atopic Dermatitis on Pediatric and Adolescent Patients With Moderate-To-Severe Disease: Results of a Real-World, Cross-Sectional Survey.Pediatric dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Therapeutic regimens for the treatment and long-term management of AD traditionally had a two-fold objective of decreasing skin inflammation and repairing the defective skin barrier. Essential treatments for AD in children should include topical moisturizers for skin hydration and prevention of flares, topical anti-inflammatory medications (e.g. corticosteroids, calcineurin inhibitors, PDE4 inhibitor), allergen/irritant avoidance, and treatment of skin infections. Treatment regimens should be severity-based, and implemented in a stepwise approach tailored to the individual patient. This stepwise approach includes initial use of emollients, gentle skin care, and escalating to more potent anti-inflammatory treatments as the disease severity increases. Currently available systemic medications should be reserved for the presence of recalcitrance to topical therapies due to associated toxicities. We believe that early treatment of AD is not only essential in treating the skin disease, but also in preventing the development of additional atopic diseases, such as food allergy, asthma and allergic rhinitis. The defective skin barrier of AD permits a route of entry for food and environmental allergens, and upon exposure, keratinocytes secrete TSLP, which activates the T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.